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The catalytic domain ofBordetella pertussis adenylate cyclase
toxin (ACT) translocates directly across the plasma membrane
of mammalian cells to induce toxicity by the production of
cAMP. Here, we use electrophysiology to examine the translo-
cation of toxin into polarized epithelial cells that model the
mucosal surfaces of the host. We find that both polarized T84
cell monolayers and human airway epithelial cultures respond
to nanomolar concentrations of ACT when applied to basolat-
eral membranes, with little or no response to toxin applied api-
cally. The induction of toxicity is rapid and fully explained by
increases in intracellular cAMP, consistent with toxin translo-
cation directly across the basolateralmembrane. Intoxication of
T84 cells occurs in the absence of CD11b/CD18 or evidence of
another specific membrane receptor, and it is not dependent on
post-translational acylation of the toxin or on host cell mem-
brane potential, both previously reported to be required for
toxin action. Thus, elements of the basolateral membrane
render epithelial cells highly sensitive to the entry of ACT in the
absence of a specific receptor for toxin binding.
The adenylate cyclase toxin (ACT),3 amultifunctional, single
polypeptide toxin, is expressed by six of the eight members of
the genus Bordetella and was discovered by detection of adeny-
late cyclase enzymatic activity in a commercial pertussis vac-
cine (1). ACT derives its cytotoxic effects from delivery of its
400-amino acid adenylate cyclase enzymatic domain into the
cell cytoplasm, resulting in the unregulated, calmodulin-
dependent conversion of ATP into cAMP (2–4). Transloca-
tion, the process by which the catalytic domain is delivered
across the cytoplasmic membrane, is unaffected by cytochala-
sin D or ammonium chloride and is dependent on the interac-
tion of the1000-amino acid cell-binding domain with the cell
membrane (5).
This cell-binding domain is homologous to the members of
the RTX (repeat-in-toxin) family of pore-forming bacterial tox-
ins, such as Escherichia coli hemolysin, HlyA, and several leu-
kotoxins from organisms such as Pasteurella hemolytica and
Actinobacillus actinomycetemcomitans (6, 7). The RTX region
of ACT oligomerizes in the cell membrane independently of
translocation, forming cation-selective pores and causing
hemolysis of erythrocytes and nonapoptotic death of nucleated
cells (8–14). Membrane interaction and pore formation by
ACT can occur in artificial lipid bilayers and liposomes and are
influenced by lipid and glycolipid composition (11, 15–18).
Although ACT intoxicates a broad range of cells and is able
to associate with artificial lipid membranes containing no
proteins, the 2-integrin, CD11b/CD18 (Mac-1), which is
expressed on phagocytic leukocytes, has been shown to in-
crease the potency of ACT by an order of magnitude and has
been considered a receptor for ACT (19). Accordingly, most of
the studies on the functional, cytotoxic effects of ACT have
focused on CD11b/CD18-positive cells, beginning with the ini-
tial observation that the oxidative burst of humanneutrophils is
inhibited by ACT (20). Mucosal epithelial cells that initially
defend against infection with Bordetella pertussis, however, do
not express CD11b/CD18. The functional and physiologic con-
sequences of intoxication of epithelial cells, or any cell type
lacking CD11b/CD18, are not well characterized.
In the present work, we use electrophysiology to measure
cAMP-dependent chloride secretion across an epithelial
monolayer as a model to investigate the ACT-cell interaction
leading to intoxication. Monolayers of polarized T84 epithelial
cells exhibit a cAMP-dependent Cl secretory response that is
quantified as short circuit current (Isc). The cell line has been
used extensively to study themechanisms and consequences of
intoxication by cholera toxin, as well as to define the physiology
of Cl secretion in the intestinal epithelium (21–23). The re-
sponsiveness of T84 monolayers to real time changes in cAMP
provides the opportunity to examine the mechanism of intoxi-
cation by ACT with a high level of sensitivity and temporal
resolution not provided by biochemical assays for cAMP. It also
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provides a model of ACT activity at mucosal surfaces where
infection with B. pertussis starts.
We find, in these studies, that the apical membrane of
polarized T84 cells almost completely resists intoxication by
ACT. The basolateral membrane, however, allows for effi-
cient translocation of the catalytic domain of ACT into the
cytosol. The same polarity of intoxication is seen in human
respiratory epithelium organ cultures, showing that the effi-
ciency of basolateral entry can be generalized to other muco-
sal surfaces.We also find that toxicity does not require mem-
brane pore formation, membrane potential as a driving
force, or post-translational acylation. Remarkably, basolat-
eral sensitivity is not explained by the polarized expression
of a specific membrane receptor.
EXPERIMENTAL PROCEDURES
Materials—All of the reagents, unless otherwise stated, were
purchased from Sigma. Cholera toxin was obtained from Cal-
biochem-Behring Corp. (San Diego, CA). Protective antigen
and edema factor from Bacillus anthracis were graciously pro-
vided by Dr. R. John Collier (Harvard Medical School). The
monoclonal antibody to ACT, 3D1, was produced as described
previously (24), as was the polyclonal antibody to ACT. The
monoclonal antibody to CD11b (M1/70) for the blocking
experiment in supplemental Fig. S2 and isotype control were
purchased from BD Pharmingen. The monoclonal antibody to
CD11b clone 44a (ATCC) was used for Western blotting.
Production and Purification of ACT—E. coli XL-1 Blue cells
(Stratagene, La Jolla, CA) containing the appropriate plasmid
construct (wild typeACT, nonacylatedACT,N489, detoxAC)
were used for toxin production as described previously (24, 25).
Cultured bacteria were centrifuged, and the resulting pellet was
resuspended in 50 mM Tris, pH 7.5, sonicated, and extracted
with 8 M urea. Urea-extracted ACTwas purified on a DEAE ion
exchange column and a calmodulin affinity column as de-
scribed previously (26). ACT was stored at 70 °C in 8 M urea,
10mMTricine, 0.5mMEDTA, 0.5mMEGTA, pH8.0. For exper-
iments containing deletion mutant N489 urea-extracted
toxin was used (24).
Cell Culture and Electrophysiology—T84 cells obtained from
ATCC were cultured on permeable supports, and measure-
ments of (Isc) were performed with 0.33-cm2 monolayers as
described previously (22, 23). Transepithelial resistance of
1000  were achieve in 8 days when 3.5  104 were seeded
onto a support membrane. The measurements of monotypic
channel functions in amphotericin permeabilized T84 mono-
layers were as described previously (27). All of the measure-
ments in the illustrated time courses are representative of at
least three independent experiments. Urea, added at the con-
centration equivalent to 10 g/ml ACT, did not change the Isc
(not shown).
Human tracheobronchial epithelial cells were obtained from
specimens resected during lung transplantation, using a proto-
col approved by the University of North Carolina Institutional
Review Board and the University of North Carolina Cystic
Fibrosis Center Tissue Culture Core, and then cultured as
described previously (28). The cells were derived from normal
single patient sources and were expanded onto permeable
Transwell-Col (12-mm diameter) supports. At confluency,
human airway epithelium cultures, also referred to as human
respiratory epithelium organ cultures, were grown with an air-
liquid interface for 4–6 weeks to generate well differentiated,
polarized cultures that resembled in vivo pseudostratified
mucociliary epithelium.Human airway epitheliaweremounted
in Ussing chambers, and chloride secretion was measured as
the transepithelial potential difference (PD/Rt  Isc) across the
monolayers (29), whereRt represents transepithelial resistance.
The cultures were studied under open circuit conditions using
a Physiologic Instruments Voltage Clamp (San Diego, CA). PD
was recorded continually, and a constant current pulse of 2–10
A was applied at 1-min intervals to calculate resistance. The
serosal side of human airway epithelium was bathed in Krebs
bicarbonate ringer solution, and the lumenal side in high potas-
sium low chloride solution. The CHO cells expressing CD11b/
CD18 or containing a neomycin resistance vector were ob-
tained as a kind gift from Dr. Douglas Golenbock and grown as
described (30).
Measurement of Intracellular cAMP—T84 cells were grown
on permeable supports under the conditions described for elec-
trophysiologic measurements. Growth medium was removed,
and ACT in Hanks’ balanced salt solution with 0.1% human
albuminwas added at the indicated concentrations to either the
apical or basolateral chamber of the support. The cells were
then incubated for 30 min at 37 °C and washed, and cAMP was
measured using the Tropix enzyme-linked immunosorbent
assay-based cAMP assay kit. Raw cAMP values were adjusted
for total cellular protein.
For experiments testing inhibition of intoxication, an ACT
mutant protein lacking enzymatic activity (detoxAC) at the
indicated concentrations was added to the indicated surface of
the monolayer and incubated at 37 °C for 15 min. Wild type
ACT was then added in the continuous presence of detoxAC.
The cells were washed, and intracellular cAMP was measured
as described above.Whenmeasuring intoxication, an equal vol-
ume of urea buffer (used for extraction of ACT during prepa-
ration as described above) was added to cells in place of
detoxAC in the control samples because the urea buffer affects
the absolute value of intoxication of some cell types, whereas it
does not affect enzymatic activity, cell association, or electro-
physiologic measurements (data not shown).
Immunofluorescence—T84 cells were grown on permeable
supports under the conditions described for electrophysiologic
measurements. Growthmediumwas exchanged forHanks’ bal-
anced salt solution with 10% heat-inactivated fetal bovine
serum with the indicated concentration of ACT added. The
cells were incubated at 37 °C for 30 min, then moved to 4 °C,
and washed, and polyclonal antibody to ACT (31) was added at
1:200. The cells were fixed in 4% paraformaldehyde. After per-
meabilizing with 0.2% saponin and blocking with goat serum,
anti-human ZO-1 antibody (Invitrogen) was added at 1:200.
Alexafluor 488-conjugated goat anti-rabbit andAlexafluor 555-
conjugated goat anti-mouse secondary antibodies were used as
secondary antibodies at 1:200. 4,6-Diamino-2-phenylindole
(Invitrogen) was used for counterstaining, and inserts were cut
and mounted on glass slides using Slowfade Gold mounting
reagent (Invitrogen). The cells were imaged by confocal
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microscopy on a Nikon TE2000 inverted microscope (Nikon
Instruments, Melville, NY) coupled to a PerkinElmer Life Sci-
ences, spinning disk confocal unit, using a Nikon PlanFluor
40  (1.3 NA) oil immersion objective lens and an Orca AG
scientific-grade cooled CCD camera (Hamamatsu Photonics
K.K., Japan). For confocal images requiring visualization of
4,6-diamino-2-phenylindole, a Zeiss LSM510 Axiovert inverted
microscope containing a purple diode laser was used, and the
images were analyzed by Zeiss LSM Image Browser software and
Image J. Adjustments to brightness, contrast, and color balance
were applied to the entire image.
Immunoblotting—T84 cells were grown as a confluent
monolayer for 8 days (time for differentiation on Transwell
inserts), or CHO cells were grown to confluence on tissue cul-
ture-treated flasks, and each cell type was scraped into lysis
buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 10 mM EDTA, 4
mM EGTA, 1% Triton X-100). The protein was measured, and
then reducing sample buffer was added followed by boiling.
Whole cell lysates were added in equal protein amounts and
separated by 10% SDS-PAGE gel, followed by transfer to
polyvinylidene difluoride membranes. The membranes were
blocked (phosphate-buffered saline, 1% Tween, 5% skim milk)
and then incubated with primary mouse anti-human mono-
clonal antibody to CD11b (44a; ATCC). The membrane was
washed, incubated with secondary antibody conjugated to
horseradish peroxidase at 1:1000, and developed by chemilumi-
nescence assay system (Pierce).
Adenylate Cyclase Enzymatic Ac-
tivity—Enzymatic activity was mea-
sured by conversion of [-32P]ATP to
[32P]cAMP in a cell-free assay as
described previously (2). Briefly, the
reaction was carried out at 30 °C and
continued for10min ina final volume
of 60 l. Each assay contained 60mM
Tricine, pH 8.0, 10 mM MgCl, 1 mM
ATP (with 2  105–5  105 cpm of
[-32P]ATP), and 1 M calmodulin.
The reaction was terminated by the
addition of 100 l of a solution con-
taining 1%SDS, 20mMATP, and 6.25
mM cAMP (including 15,000–20,000
cpm of [3H]cAMP/tube for calcula-
tion of recovery).
For experiments addressing block-
ingof cell associationbydetoxAC, the
conditions were as described for
measurement of inhibition of intoxi-
cation as described above.Again,wild
type ACT was added in the continu-
ous presence of detoxAC. Under
these conditions, urea did not affect
the degree of cell association.
RESULTS
Rapid Induction of Isc by ACT at
the Basolateral Surface but Not the
Apical Surface of the T84Monolayer—
Application ofACT to the basolateral surface of a polarizedT84
monolayer results in concentration-dependent, transepithelial
chloride secretion, measured as short circuit current, Isc (Fig.
1A). There is little or no response to ACT applied to the apical
surface of the monolayer (Fig. 1B). The subsequent addition of
adenosine causes a robust increase in Isc, demonstrating that
these cells are intact and able to secrete Cl (32). The differen-
tial response of the two surfaces to ACT can also be measured
biochemically as ACT-catalyzed intracellular cAMP accumula-
tion (Fig. 1C). ACT added at 1.42 g/ml (8.5 nM) induces a
maximal Isc because the toxin-generated intracellular cAMP
saturates the cellular mechanisms of chloride secretion in T84
cells.
To show that ACT-induced Isc results from translocation of
the ACT catalytic domain into the cytosol and subsequent pro-
duction of intracellular cAMP and not from other functions of
ACT that could induce Isc, such as oligomeric pore formation or
Ca2	 influx (33), we examined the dependence of toxin-in-
duced Isc on the cAMP-gated K	 channel KCNQ1/KCNE3.
This channel is required for the cAMP-induced Isc and is
strongly inhibited byBa2	 (34). Fig. 2 (A andB) shows that Ba2	
inhibits Isc induced by both ACT and the cAMP-agonist vaso-
active intestinal peptide (VIP), which is used as a positive con-
trol (22). Ba2	 inhibits ACT-induced Isc even when applied
after the addition of toxin. The inability of VIP to increase the
Isc elicited by a maximal concentration of ACT (Fig. 2C) is fur-
ther evidence that increased intracellular cAMP is responsible
FIGURE 1. Effects of concentration, time, and monolayer polarity on the ACT-induced chloride secretory
response and ACT-generated intracellular cAMP in T84 monolayers. A, Isc measured after ACT added to the
basolateral surface at the indicated concentrations. B, Isc measured after ACT added to the apical or basolateral
surface or adenosine to the apical surface at the indicated concentrations. C, ACT-induced intracellular cAMP
when ACT is added to either the apical or basolateral surface of the monolayer.
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for the ACT-induced chloride response. On the other hand,
carbachol, which induces Isc by increasing the intracellular
Ca2	 concentration (21), acts synergistically with cAMP and
causes a rapid and robust increase in maximal Isc after the
response from the addition of ACT or VIP (Fig. 2C). These data
show that the Cl secretion induced by ACT results from tox-
in-generated intracellular cAMP
and not from transmembrane pore
formation or Ca2	 influx.
As an additional control to assure
that the ACT-generated transmem-
brane pore is not contributing to the
Isc elicited by toxin addition, we
used an ACT protein (N489) that
lacks the catalytic domain and is
unable to catalyze the production of
cAMP from ATP (24). This mutant
toxin also exhibits greater pore-
forming activity than nativeACT, as
measured by its hemolytic potency.
As shown in Fig. 2D, N489 does
not induce Isc when applied to the
basolateral membranes of T84 cells.
Similarly, the monoclonal antibody
3D1, which prevents delivery of the
catalytic domain, also blocks the
ACT-induced Isc (24). Together,
these data establish definitively
that it is the production of cAMP
by ACT, not any of its other func-
tions, that is responsible for the
resultant Isc.
The increase in Isc begins within
seconds after the addition of ACT,
an observationmade possible by the
real time measurements of the T84
monolayer system. The rapidity is
consistent with the concept of
direct translocation of the ACT cat-
alytic domain across the membrane
and is almost equivalent in tempo to
the response to VIP, a stimulator of
endogenous adenylyl cyclase. In
contrast, the Isc response to other
cAMP-producing toxins, cholera
toxin of Vibrio cholerae and edema
toxin of B. anthracis, is delayed
because of the intracellular traffick-
ing required for the activity of these
proteins (supplemental Fig. S1).
Polarized Sensitivity of Human
Respiratory Epithelial Cultures to
ACT—To test whether the finding
of selective sensitivity of the baso-
lateral membrane of T84 monolay-
ers to ACT could be generalized to
the respiratory epithelium, we
measured the electrophysiologic
response of human airway epithelial cultures to ACT. To pre-
pare the airway epithelial layers, cells from human tissue spec-
imens are grown on collagen-coated semi-permeable supports,
resulting in an in vitro pseudostratified mucociliary epithelium
that recapitulates in vivo morphology (28). Supports are
mounted in Ussing chambers in which chloride secretion is
FIGURE 2. Increases in Isc specifically caused by translocation of the catalytic domain of ACT and stimu-
lation of cAMP-dependent chloride secretion. A, Isc measured after addition of ACT (1.42 g/ml) or VIP (1 nM)
with or without BaCl2 (3 mM). B, measurement at final time point of Isc stimulated by ACT (1.42 g/ml) alone
(column 1), ACT added before BaCl2 (column 2), ACT added after BaCl2 (column 3), VIP (1 nM; column 4), and VIP
added before BaCl2 (column 5). C, Isc measured after addition of ACT (1.42 g/ml) or VIP (1 nM) with or without
subsequent addition of carbachol (10 M). D, Isc measured after addition of ACT (1.42 g/ml; column 1), N489
(1.42 g/ml; column 2), ACT incubated with mouse whole IgG control (column 3), and ACT incubated with
mouse mAb 3D1 (column 4).
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measured as PD. The respiratory epithelium is first treatedwith
amiloride to block Na	 transport, resulting in a decrease in PD
to a new steady state (35). The addition of ACT (0.95 g/ml) to
apical membranes does not induce a change in PD (Fig. 3A).
Subsequent addition of the cAMP agonist, forskolin, however,
does cause an increase in PD. The addition of CFTR(inh)-172, a
thiazolidinone that blocks transport across the apical cAMP-
dependent chloride channel, CFTR, confirms that PD reflects
chloride current (36). The nucleotide UTP activates Ca2	-de-
pendent/CFTR-independent Cl secretion and is added as an
additional control. Fig. 3B shows a similar experiment in which
there is no response to apically added ACT (0.95 g/ml), but
basolateral addition of ACT results in an increase in PD. As
confirmed by apical (but not basolateral) addition of
CFTR(inh)-172, the change in PD results from cAMP-depen-
dent Cl secretion. Thus, at this concentration, ACT intoxi-
cates human respiratory epithelium only when added at the
basolateral surface.
Association of ACT with the Basolateral and Apical Surfaces
of the T84 Monolayer—We next used epifluorescence confocal
microscopy to determine whether the differential sensitivity of
apical and basolateral membranes of the T84 monolayer to
ACT can be explained by a failure of toxin to associate with the
apical surface. Here, live cells were incubatedwithACT applied
either apically or basolaterally at 37 °C for 30min. After immer-
sion in fresh buffer at 4 °C, the monolayers were immuno-
stained for ACT with a rabbit polyclonal anti-ACT antibody.
The cells were washed again at 4 °C, fixed, permeabilized with
0.2% saponin, and immunostained for the tight junction asso-
ciated protein ZO-1 to mark the apical membrane. Because the
cells were intact during immunostaining, ACT identified by
labeling with the antibody can only be associated with the outer
surfaces of the cells. Fig. 4A shows that ACT applied to the
apical surface (10g/ml) appears as distinct puncta at the apical
surface of the T84monolayer. There was no association detect-
able by epifluorescence microscopy at 1 g/ml (data not
shown). Shown in Fig. 4B are lateral views of the monolayer
with full depth-of-field focused reconstructions generated from
compilation of 0.3-mZ-sections of the monolayer. These col-
lapsed views show thatACTassociateswith the cellmembranes
whether added apically (Fig. 4B, top panels) or basolaterally
(Fig. 4B, bottom panels). The signal from ACT associated with
the basolateral membrane is greater than that associated with
the apical membrane. This may be either due to enhancement
of association of ACT with cell membranes by components of
the basolateral surface or due to the larger cell membrane sur-
face area exposed to ACT when added to the basolateral sur-
face.Onboth surfaces, ACT forms clusters under these staining
conditions.
Association of ACT with apical or basolateral membranes
was not detected by epifluorescence microscopy when ACT
was added to cells at 4 °C, suggesting either a low affinity bind-
ingmechanism or a requirement formembrane rearrangement
that is inhibited by low temperatures. Cell-associated ACTwas
also not detected when fixed and permeabilized with saponin
prior to immunostaining for ACT. This suggests that saponin
extracts membrane-associated toxin, possibly because of inter-
action of ACT with membrane lipids.
To test whether ACT interacts with a specific receptor at
the apical membrane, we used detoxAC (13, 37) as a compet-
itive inhibitor. In these studies, detoxAC was applied to the
apical surface of the T84 monolayer at 37 °C for 15 min.
Subsequently, a range of concentrations of wild type ACT
was added at 37 °C for 30 min in the continuous presence or
in the absence of detoxAC. The cells were washed to remove
free toxin, and cell association wasmeasured by in vitro assay
for adenylate cyclase enzymatic activity from whole cell
lysates (the values were corrected for background endoge-
nous cellular adenylyl cyclase activity). This sensitive tech-
nique has been used as a quantitative measure of cell associ-
ation of ACT with multiple other cell types (25, 38, 39), and
cell-associated ACT is detectable by this assay when cells are
exposed to 300 ng/ml of toxin. In the presence of excess
detoxAC (30 g/ml), apically associated ACT is not dis-
placed. Thus, toxin association with the apical surface is not
consistent with binding to a specific receptor.
To test for specific binding of ACT to the basolateral surface,
we first confirmed that T84 cells do not express CD11b
(supplemental Fig. S2).We then testedwhether detoxAC inhib-
FIGURE 3. Polarized sensitivity of human respiratory epithelium organ
cultures to ACT. Treatments were added to the specified sides of the epithe-
lia. Forskolin (1  105 M), a cell-permeable activator of cellular adenylyl
cyclase, was used as a positive control. Amiloride (1  104 M), a sodium
channel blocker, was used as a control for specificity of PD to chloride secre-
tion. UTP (1  104 M) activates calcium dependent/CFTR-independent chlo-
ride secretion and was used as a positive control. CFTR(inh)-172 (1  105 M)
is a specific inhibitor of the apically located, cAMP-dependent CFTR. A, no
chloride response after apical addition of ACT (0.95 g/ml) but response to
apically added forskolin. B, no chloride response after apical addition of ACT
(0.95 g/ml) but response to basolaterally added ACT.
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its intoxication of polarized T84 cells whenACT is added to the
basolateral monolayer surface. Intoxication (intracellular
cAMP) was measured because ACT adheres to the polyester
support underlying the basolateral cell surface, preventing
accurate measurement of enzymatic activity when ACT was
added basolaterally. We found that in the continuous presence
of excess detoxAC (or urea as a vehicle control), intoxication by
ACT is not competitively inhibited (Fig. 5B). The results are
represented, here, in log scale for clarity of comparison, rather
than linear scale as shown in Fig. 1C.
As a positive control for the com-
petition experiments represented in
Fig. 5B, we show that detoxAC does
inhibit intoxication of CHO cells
expressing CD11b/CD18 (Fig. 5C).
As a positive control for the experi-
ments represented in Fig. 5A, we
have also confirmed that inhibition
of intoxication of these CHO cells is
due to displacement of cell-associ-
ated enzymatic activity (not shown).
Thus, although ACT appears to
associate with both apical and
basolateral membranes of T84
cells, we believe that the very lim-
ited quantity detected on the api-
cal surface is not pathophysiologi-
cally relevant. Most importantly,
the mechanism of association of
ACT with the basolateral surface,
in contrast to that seen in CHO
cells expressing CD11b/CD18, is
not consistent with binding to a
specific receptor.
Translocation across the Basolat-
eral Surface Independent of Acyla-
tion of the Toxin or Membrane
Potential—Translocation of ACT
has been shown, in prior studies, to
be driven by membrane potential
FIGURE 4. ACT associates with both surfaces of the T84 monolayer. A, immunofluorescent staining of the
apical surface of a polarized T84 monolayer grown on Transwell insert. Tight junctions (red) are labeled by
mouse monoclonal antibody to ZO-1. ACT 10 g/ml is labeled with rabbit polyclonal antibody to ACT (green).
Shown is a Z-section of the apical surface of the monolayer. B, shown are full-transparency, lateral views of
three-dimensional reconstructions of monolayers imaged by 0.3-m Z-sections. Immunofluorescent staining
of monolayers after either apical (apical ACT) or basolateral (baso ACT) addition of ACT. ACT 10 g/ml was
added to either side of the monolayer (right) or not added (left) and stained with polyclonal antibody to ACT
(green) prior to fixation or permeabilization. Tight junctions are labeled by monoclonal antibody to ZO-1 (red).
The nuclei are stained with 4,6-diamino-2-phenylindole.
FIGURE 5. detoxAC does not compete for association of ACT with the apical surface nor intoxication of the basolateral surface by ACT. A, association of
ACT with the apical surface measured by retained enzymatic activity after addition of ACT followed by washing. ACT was added in the continuous presence or
absence of detoxAC (30 g/ml). B, intracellular cAMP measured after addition of ACT to the basolateral surface in the continuous presence of detoxAC (20
g/ml) or urea solvent. C, intracellular cAMP was measured after addition of ACT to CHO cells expressing CD11b/CD18 in the continuous presence or absence
of detoxAC (20 g/ml) or urea.
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and affected by post-translational acylation of the toxin mole-
cule. Otero et al. (41) have demonstrated by patch clamping of
frog cardiac myocytes and measurement of calcium current
through cell type-specific cAMP-stimulated calcium channels
that translocation by ACT depends on an inwardly directed,
negative membrane potential. Similarly, insertion of a nega-
tively charged peptide into the catalytic domain of ACT pre-
vents translocation across the cytoplasmic membrane of sheep
erythrocytes (42). To address the charge dependence of ACT
translocation across the basolateral membrane of polarized
T84 cells, we applied a voltage clamp to T84 cell basolateral
membranes at the desired membrane potential and measured
the Isc response to ACT. The basolateral membrane was elec-
trically isolated by selectively permeabilizing the apical mem-
brane of the T84 monolayer to monovalent ions by application
of amphotericin B using buffers containing K	 as the primary
charge-carrying cation (see “Experimental Procedures”). Under
these conditions, the transepithelial Isc recorded represents K	
transport across the basolateral membrane (termed Isc-blK)
(27). Because the ACT-induced Isc in T84 cells requires the
activation of the basolateral cAMP-gated K	 channel (Fig. 2),
translocation of toxin across the basolateral membrane can be
measured in this permeabilized cell system under defined baso-
lateral membrane potential as a toxin-induced Isc-blK.We find
that ACT translocates across the basolateral membranes to
induce an increase in Isc-blK with transmembrane potential
held over the full range of physiologic potentials: 35, 0, or 35
mV (Fig. 6,A–C). Thus, the basolateralmembranes of polarized
T84 cells allow translocation even under depolarized
conditions.
Post-translational, covalent acylation by the acyl-transferase
CyaC is required for hemolytic activity and for fully functional
translocation/intoxication by ACT, although it is not required
for in vitro enzymatic activity (13, 25, 43–45). J774 cells express
CD11b/CD18 and are intoxicated by nonacylated ACT, but
with a 50-fold reduction in toxin potency. Cell lines that lack
CD11b/CD18 expression are resistant to intoxication by non-
acylated ACT (13, 25, 44). When applied to basolateral mem-
branes of T84 cells, however, nonacylated ACT induces chlo-
ride secretion (Fig. 6D). Thus, unlike other cell lines lacking
CD11b/CD18 expression, T84 cell monolayers are susceptible
to intoxication by nonacylated ACT added to the basolateral
surface, providing further evidence that the basolateral surface
is atypically permissive to toxin translocation.
DISCUSSION
The results of these studies show that ACT can intoxicate
polarized epithelial cells, including those that line the human
respiratory tract. Although the mucosal surface of epithelial
monolayers resists intoxication, the basolateral surface is highly
sensitive. Differential sensitivity across epithelial monolayers
has been observed for other bacterial toxins. Intoxication of
FIGURE 6. Voltage independence of translocation and response to nonacylated ACT at the basolateral surface of the T84 monolayer. A–C, Isc measured
following addition of ACT (1.42 g/ml) after clamping at 	35 (A), 0 (B), and 35 mV (C). For all figures, the apical membrane was permeabilized with 20 M
amphotericin B in buffer containing K	 as the primary charge-carrying ion, and then the voltage across the basolateral membrane was clamped as indicated.
D, Isc measured after addition of ACT (1.42 g/ml) or nonacylated ACT (1.4 g/ml). VIP was added to calibrate the response.
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epithelial cells by edema toxin has been shown, using the T84
monolayer system, to occur selectively from the basolateral sur-
face (46) because of basolateral sequestration of the edema
toxin receptor. Glycophosphatidylinositol-linked proteins are
greatly enriched at the apical surface (47); some toxins, such as
aerolysin of Aeromonas hydrophila and -toxin of Clostridium
septicum (48, 49), use these glycophosphatidylinositol-linked
proteins as their receptors and have different effects on polar-
ized epithelial monolayers (Madin-Darby canine kidney and
Fisher rat thyroid cells) depending on the side of themonolayer
exposed to toxin and the distribution of glycophosphatidylino-
sitol-linked proteins (50). The enterotoxin of Clostridium per-
fringens, which associates with and changes the function of
claudins, decreases transepithelial resistance from the basolat-
eral surface of polarizedMadin-Darby canine kidney monolay-
ers but not from the apical surface (51).
As our findings demonstrate, however, the interaction
between ACT and the components of the T84monolayer baso-
lateralmembrane cannot be explained by basolateral sequestra-
tion of a specific receptor. Our results suggest that ACT may
interact with membrane lipids to translocate its catalytic
domain into the cytoplasm. An interaction with lipids would be
consistent with our findings that ACT association with the
membrane was reduced by cold temperatures and by applica-
tion of saponin. It is known that ACT is functional in artificial
lipid bilayers and liposomes in the absence of proteins, and the
interaction is affected by lipid/glycolipid composition (11, 15,
16). Lipidmembrane composition of whole cells also affects the
function and surface distribution of other pore-forming RTX
toxins, such as the leukotoxins ofMannheimia hemolytica (52)
andA. actinomycetemcomitans (53). There are dramatic differ-
ences in lipid composition of the apical and basolateral mem-
branes of epithelial cells (54), with the apical membrane char-
acterized by different lipid species and amore ordered, or rigid,
lipid composition.
Extracellular factors may also contribute to the polarity of
intoxication by ACT. The luminal surfaces of respiratory and
gastrointestinal epithelia are coated by a mass of glycoproteins,
the glycocalyx, which is present on the apical surface of mature
T84 monolayers (55) and respiratory epithelium organ cul-
tures. The glycocalyx serves as a barrier to multiple pathogens
in the gastrointestinal tract (56) and to adenovirus in the respi-
ratory tract (57, 58). It has recently been reported byMorova et
al. (59) thatN-linked glycosylation is required for ACT toxicity
in CHO cells expressing CD11b/CD18 and that excess sialic
acid and other oligosaccharides strongly inhibit the association
of ACT with the surfaces of cells expressing CD11b/CD18.
Thus, it is possible that complex oligosaccharides of the gly-
cocalyx may bind to ACT and block intoxication by present-
ing “nonfunctional” binding sites distant from the apical
membrane.
ACT is secreted at the luminal surface of the airway epithe-
lium during infection with B. pertussis, which adheres to the
bases of cilia (60–64). Human pathologic specimens from chil-
drenwho have died from severe pertussis show extensive denu-
dation of the epithelium, filling of the alveoli with copious fluid,
and a robust inflammatory response to infection (65, 66). The
disruption of themucosal surfacewould expose the basal side of
the epithelium to ACT. Subsequent intoxication of the epithe-
lial cells, resulting in chloride secretion, would then contribute
to the accumulation of bronchoalveolar fluid that is character-
istic of severe pertussis. Furthermore, intoxication of epithelial
cells by ACT may contribute to pulmonary inflammation. B.
pertussis, only when expressing ACT, stimulates release of the
proinflammatory cytokine, interleukin-6, from nonpolarized
human tracheal epithelial cells (67).
Multiple cell types will be exposed to ACT during infection
with B. pertussis. We show, for the first time, that mucosal epi-
thelial cells are a physiologically relevant target of ACT-in-
duced toxicity in the absence of CD11b/CD18 or another
specific receptor. Although CD11b/CD18 expression greatly
augments the intoxication of cells by ACT, it is clearly not
required for effective intoxication. We suggest that CD11b/
CD18 enhances translocation by altering an underlying non-
competitive mechanism of cell association, and studies are
underway to further characterize the interaction of ACT with
other cell types not expressing CD11b/CD18.
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